Institute for Clinical Chemistry, Medical Faculty Mannheim of the University of Heidelberg, University Hospital Mannheim, Theodor-Kutzer-Ufer 1-3, Mannheim, Germany.
J Exp Clin Cancer Res. 2012 Jun 8;31(1):56. doi: 10.1186/1756-9966-31-56.
The progression of many solid tumors is characterized by the release of tumor-associated proteases and the detection of tumor specific proteolytic activity in serum specimens is a promising diagnostic tool in oncology. Here we describe a mass spectrometry-based functional proteomic profiling approach that tracks the ex-vivo degradation of a synthetic endoprotease substrate in serum specimens of colorectal tumor patients.
A reporter peptide (RP) with the amino acid sequence WKPYDAAD was synthesized that has a known cleavage site for the cysteine-endopeptidase cancer procoagulant (EC 3.4.22.26). The RP was added to serum specimens from colorectal cancer patients (n = 30), inflammatory controls (n = 30) and healthy controls (n = 30) and incubated under strictly standardized conditions. The proteolytic fragment of the RP was quantified with liquid chromatography / mass spectrometry (LC/MS).
RP-spiking showed good intra- and inter-day reproducibility with coefficients of variation (CVs) that did not exceed a value of 10%. The calibration curve for the anchor peptide was linear in the concentration range of 0.4 - 50 μmol/L. The median concentration of the RP-fragment in serum specimens from tumor patients (TU: 17.6 μmol/L, SD 9.0) was significantly higher when compared to non-malignant inflammatory controls (IC: 11.1 μmol/L, SD 6.1) and healthy controls (HC: 10.3 μmol/L, SD 3.1). Highest area under receiver operating characteristic (AUROC) values were seen for discrimination of TU versus HC (0.89) followed by TU versus IC (0.77). IC and HC could barely be separated indicated by an AUROC value of 0.57. The proteolytic activity towards the RP was conserved in serum specimens that were kept at room temperature for up to 24 hours prior to the analysis.
The proteolytic cleavage of reporter peptides is a surrogate marker for tumor associated proteolytic activity in serum specimens of cancer patients. A simple, robust and highly reproducible LC/MS method has been developed that allows the quantification of proteolytic fragments in serum specimens. The preanalytical impact of sample handling is minimal as the tumor-associated proteolytic activity towards the reporter peptide is stable for at least up to 24 h. Taken together, the functional protease profiling shows characteristics that are in line with routinely performed diagnostic assays. Further work will focus on the identification of additional reporter peptides for the construction of a multiplex assay to increase diagnostic accuracy of the functional protease profiling.
许多实体瘤的进展特征是肿瘤相关蛋白酶的释放,并且在血清标本中检测到肿瘤特异性蛋白水解活性是肿瘤学中很有前途的诊断工具。在这里,我们描述了一种基于质谱的功能蛋白质组学分析方法,该方法可跟踪合成内切蛋白酶底物在结直肠肿瘤患者的血清标本中的体外降解情况。
合成了具有已知半胱氨酸内肽酶癌促凝剂(EC 3.4.22.26)切割位点的报道肽(RP),其氨基酸序列为 WKPYDAAD。将 RP 添加到结直肠癌患者(n = 30)、炎症对照(n = 30)和健康对照(n = 30)的血清标本中,并在严格标准化的条件下孵育。用液相色谱/质谱(LC/MS)定量 RP 的蛋白水解片段。
RP 加标显示出良好的日内和日间重现性,变异系数(CV)不超过 10%。锚定肽的校准曲线在 0.4-50 μmol/L 的浓度范围内呈线性。与非恶性炎症对照(IC:11.1 μmol/L,SD 6.1)和健康对照(HC:10.3 μmol/L,SD 3.1)相比,肿瘤患者(TU:17.6 μmol/L,SD 9.0)血清标本中 RP 片段的浓度明显更高。区分 TU 与 HC 的受试者工作特征(ROC)曲线下面积(AUROC)最高(0.89),其次是 TU 与 IC(0.77)。IC 和 HC 几乎无法区分,AUROC 值为 0.57。在分析前将血清标本在室温下保存长达 24 小时,RP 的蛋白水解活性仍然保持不变。
报道肽的蛋白水解切割是癌症患者血清标本中肿瘤相关蛋白水解活性的替代标志物。已经开发了一种简单、稳健且高度可重复的 LC/MS 方法,可用于定量血清标本中的蛋白水解片段。样本处理的分析前影响最小,因为报道肽的肿瘤相关蛋白水解活性至少在 24 小时内是稳定的。总的来说,功能蛋白酶谱分析具有与常规诊断检测一致的特征。进一步的工作将集中于鉴定其他报道肽,以构建用于提高功能蛋白酶谱分析诊断准确性的多重分析。